SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is generating massive market buzz following its high-profile public debut, with investors deeply divided over whether the company's multi-trillion dollar valuation reflects revolutionary long-term potential or unsustainable hype. The community is actively debating the stock's future, as traders closely monitor high volatility and look ahead to upcoming options trading, index inclusion, and the potential impact of insider lock-up expirations.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending following a Bloomberg report that the streaming company is exploring a potential sale, with discussions reportedly underway with at least one major U.S. media entity. The community is actively debating the credibility of these buyout rumors and the company's long-term strategic value, leading to significant volatility as traders analyze the potential for a premium acquisition against the backdrop of an increasingly competitive streaming landscape.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean Ltd. is currently trending as investors weigh strong backlog growth and improved operational efficiency against geopolitical uncertainty in the Strait of Hormuz. The community is actively debating whether the stock's recent performance is tethered more to daily fluctuations in oil prices or the long-term potential of its merger with Valaris and ongoing debt reduction efforts.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate the potential for future adoption versus extreme price volatility and frustration over a lack of major updates from the Flexa team. While community sentiment is heavily polarized between long-term holders citing the utility of the Anvil and Flexa ecosystem and critics pointing to the token's persistent downward trend, active discussions remain focused on legislative catalysts like the CLARITY Act and alleged institutional activity in staking pools.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is facing intense retail volatility as investors weigh its role as a key enterprise AI player against recent price consolidation and the market's broader rotation toward speculative IPOs and sector de-leveraging. The community remains deeply polarized, with many long-term holders treating recent pullbacks as prime accumulation zones while vocal detractors criticize the stock's valuation and the broader software sector's recent weakness.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is surging as investors react to a significant regulatory delay for its primary competitor, Aquestive Therapeutics, effectively extending SPRY's lead as the only approved needle-free epinephrine treatment. The community is actively discussing a potential short squeeze, fueled by high short interest and institutional accumulation, as the company scales its global market presence.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing heightened interest as investors weigh record-high Nasdaq levels against volatile geopolitical developments, including U.S.-Iran tensions. The community is actively debating the sustainability of the AI-driven tech rally and the risks associated with holding triple-leveraged instruments in an environment characterized by inflation concerns and potential policy shifts.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

TROLL is capturing significant community attention as investors position it alongside established meme coins, with many touting its long-standing cultural relevance and potential for exponential growth. Enthusiasm is centered on the project's ownership of original IP rights and active grassroots campaigns aimed at driving massive adoption within the broader meme ecosystem.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the stock surges following a major announcement that it is breaking ground on an expanded multi-billion dollar semiconductor packaging campus in Arizona. The community is actively discussing this expansion as a key play on domestic semiconductor onshoring and the growing necessity of advanced packaging to support the AI supply chain.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors focus on a pending Supreme Court case regarding induced infringement, while actively debating the long-term impact of new cardiovascular guidelines and the company's path toward sustainable cash flow. Community discussion remains polarized, centering on the potential for a strategic buyout, the significance of the 2026 guideline updates, and skepticism regarding board management following the company's recent reverse split and financial restructuring.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) have earned an average rating of "Buy" from the eight analysts that are presently covering the company, MarketBeat reports. One...

HC Wainwright Issues Positive Estimate for IKT Earnings

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for Inhibikase Therapeutics in a research report...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded Inhibikase Therapeutics to a "strong-buy" rating in a report on Wednesday...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update

Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH initiated coverage on Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $4.00 target price for the company...

FY2025 Earnings Forecast for IKT Issued By Lifesci Capital

Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Stock analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Inhibikase Therapeutics in a report issued on Monday...

Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% - Still a Buy?

Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.4% - Time to Buy...

Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating

Lifesci Capital raised Inhibikase Therapeutics to a "strong-buy" rating in a report on Monday...

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

Current Price	$1.67
Prev Close	$1.67
Open	$1.68
Dividend Yield	0.00%
50-Day Moving Average	$1.78
Beta	1.20
Avg. Volume	716,127.56
PE Ratio	-3.84

52-Week High	$2.26
52-Week Low	$1.33
Market Capitalization	$220.49M
EPS (Annual)	-$0.4909
Price to Book	1.32
Revenue Per Employee	$0.00

IKTInhibikase Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IKT News